We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.8B
AUM Growth
+$1.2B
Cap. Flow
+$591M
Cap. Flow %
8.68%
Top 10 Hldgs %
38.38%
Holding
154
New
24
Increased
52
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$204M
2
PRGO icon
Perrigo
PRGO
+$111M
3
ABBV icon
AbbVie
ABBV
+$99.2M
4
CELG
Celgene Corp
CELG
+$71.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$70.4M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$169M
2
ELV icon
Elevance Health
ELV
+$69M
3
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
+$56.2M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$53.1M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$52.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.58%
2 Financials 1.18%
3 Technology 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQL
76
DELISTED
Arqule Inc
ARQL
$12.3M 0.18%
5,702,000
+1,336,000
+31% +$3.01M
ABT icon
77
Abbott
ABT
$191B
$11.7M 0.17%
305,000
-95,000
-24% -$3.5M
ILMN icon
78
CALL
Illumina
ILMN
$29.3B
$11.1M 0.16%
+102,800
New +$9.42M
MRGE
79
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$10.7M 0.16%
4,628,500
+332,500
+8% +$809K
SVA
80
DELISTED
Sinovac Biotech, Ltd
SVA
$10M 0.15%
1,637,500
-246,700
-13% -$1.49M
ZTS icon
81
Zoetis
ZTS
$33B
$9.12M 0.13%
+279,000
New +$8.9M
DVA icon
82
DaVita
DVA
$15.5B
$9.06M 0.13%
143,000
+13,000
+10% +$763K
FRX
83
CALL
DELISTED
FOREST LABORATORIES INC
FRX
$9.01M 0.13%
+150,000
New +$7.55M
GEVA
84
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$8.41M 0.12%
130,000
– –
NSPR icon
85
InspireMD
NSPR
$32.3M
$8.35M 0.12%
1
– –
FRX
86
DELISTED
FOREST LABORATORIES INC
FRX
$8.34M 0.12%
139,000
+19,000
+16% +$956K
VCRA
87
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$6.99M 0.1%
447,500
– –
XNCR icon
88
Xencor
XNCR
$1.44B
$6.42M 0.09%
+702,600
New +$6.03M
UTHR icon
89
United Therapeutics
UTHR
$25.9B
$6.22M 0.09%
+55,000
New +$4.96M
CBST
90
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$6.2M 0.09%
90,000
-814,200
-90% -$52.7M
MDXG icon
91
MiMedx Group
MDXG
$645M
$6.12M 0.09%
+700,000
New +$4.29M
PTX
92
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$5.85M 0.09%
232,080
– –
CRIS icon
93
Curis
CRIS
$9.67M
$5.5M 0.08%
975
– –
CVD
94
DELISTED
COVANCE INC.
CVD
$5.2M 0.08%
59,000
+11,000
+23% +$952K
TECH icon
95
Bio-Techne
TECH
$11.2B
$4.73M 0.07%
200,000
-864,000
-81% -$18.7M
QCOR
96
CALL
DELISTED
QUESTCOR PHARMA INC
QCOR
$4.63M 0.07%
+85,000
New +$5.02M
FATE icon
97
Fate Therapeutics
FATE
$267M
$4.41M 0.06%
+702,000
New +$4.42M
SUPN icon
98
Supernus Pharmaceuticals
SUPN
$2.74B
$4.37M 0.06%
580,000
-59,400
-9% -$415K
QCOR
99
DELISTED
QUESTCOR PHARMA INC
QCOR
$4.36M 0.06%
80,000
– –
UPI
100
DELISTED
UROPLASTY INC-NEW
UPI
$3.94M 0.06%
1,443,500
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2013 Portfolio in Review

As of Q4 2013, OrbiMed held 154 positions worth $6.8B, up 21% from $5.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $591M of net new capital in Q4 2013, opening 24 new positions and adding to 52 existing holdings. Its largest new stake was RELYPSA INC COM: 9,941,549 shares worth $249M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 84% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Merck, an estimated $169M trimmed.

  • OrbiMed's largest Q4 2013 buy was RELYPSA INC COM: 9,941,549 shares worth $249M.
  • OrbiMed added most to AbbVie in Q4 2013, an estimated $99.2M increase.
  • OrbiMed's biggest Q4 2013 reduction was Merck, cutting an estimated $169M.
  • OrbiMed fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $56.2M.
  • OrbiMed's ten largest holdings make up 38% of its $6.8B portfolio in Q4 2013.
  • OrbiMed opened 24 new positions and closed 34 in Q4 2013.
  • OrbiMed's portfolio value rose 21% quarter-over-quarter to $6.8B.

Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.